Studies to Highlight Advances in Detection, Treatment of Prostate, Renal Cancers
ALEXANDRIA, Va. – Three key studies from the 2013 Genitourinary Cancers Symposium will be featured in an embargoed presscast for reporters on Tuesday, February 12, 2013, from 12:00-1:30 PM (EST). These important studies will focus on the latest advances being made in the screening and management of several genitourinary cancers. The presscast will be moderated by Bruce J. Roth, MD, a member of the 2013 Genitourinary Cancers Symposium News Planning Team and chair of ASCO’s Cancer Communications Committee.
During the presscast, which will be held via live teleconference and webinar, researchers will present results from the following three studies:
- A study on the odds of developing low-, intermdiate-, and high-risk disease in men with AJCC stage T1cN0M0 PSA-detetected prostate cancer (Hong Zhang, MD, PhD, University of Rochester Medical Center, Rochester, NY)
- A trial that evaluated outcomes in men with high-risk prostate cancer who were treated with pelvic radiotherapy and 36 or 18 months of androgen blockade (Abdenour Nabid, MD, FRCP(C), Centre Hospitalier Universitaire de Sherbrooke, Sherbrooke, Quebec City)
- A population-based study that examined the uses and outcomes of surveillance versus surgery in management of small renal masses (William C. Huang, MD, NYU School of Medicine, New York, NY)
Genitourinary cancers include those of the prostate, kidney, bladder and testis, as well as less common cancers such as those of the penis, ureters and other urinary organs. In 2012, an estimated 390,000 people in the United States were diagnosed with genitourinary cancers, with an estimated 58,000 deaths. The most common genitourinary cancer is prostate cancer, which according to estimates, was diagnosed in more than 241,000 men in the United States in 2012, and claimed more than 28,000 lives.1
This year’s Symposium will take place February 14 - 16 2013, at the Rosen Shingle Creek in Orlando and feature 475 abstracts on the latest research in genitourinary cancers.
Three leading medical specialty societies co-sponsor the three-day, multidisciplinary symposium, including the American Society of Clinical Oncology (ASCO), the American Society for Radiation Oncology (ASTRO) and the Society of Urologic Oncology (SUO).
Media Registration: To register to attend the meeting or participate in the presscast, visit ASCO's online Media Headquarters. The deadline to register for the presscast is Friday, February 8. Please note: If you were already credentialed for the 2012 ASCO Annual Meeting, the 2012 Breast Cancer Symposium or the 2013 Gastrointestinal Cancers Symposium, you will automatically receive the presscast login information and do not have to register again. For further assistance please contact Nicole Racadag at email@example.com or 571-483-1354. News and other information about the Symposium will be made available at gucasym.asco.org.
1 Cancer Facts and Figures 2012. Atlanta, GA: American Cancer Society: 2012
# # #